Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BERGEN BRUNSWIG DRUG SALES UP 12% TO $3.4 BIL

Executive Summary

BERGEN BRUNSWIG DRUG SALES UP 12% TO $3.4 BIL in fiscal 1989, and revenues from the drug/health care division climbed 11.9% to $869.4 mil. in the last quarter of the year (ended Aug. 31). The Orange, California-based drug wholesaler and consumer electronics firm announced year-end results on Oct. 2. The drug division's operating profits for the fourth quarter were 7.5% higher than in the previous year at $23.5 mil. and spiraled 18.2% to $99.6 mil. for the full year. Bergen Brunswig Chairman and CEO Emil Martini, Jr. attributed the over-18% jump in division operating profits to "a slightly higher gross profit margin rate coupled with a reduction in the overall operating expense." The firm recorded an overall sales increase for the year of 12.5% to $3.9 bil. Fourth quarter consolidated revenues rose 11% to $997.8 mil. Bergen's Commtron Corp. had sales of $550 mil. for the year, a 16% increase over 1988 sales of $475 mil.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel